This review found that oral bacteria extracts improve symptoms in patients with chronic bronchitis and chronic obstructive pulmonary disease. There was insufficient evidence to suggest that they prevent exacerbations. Adverse effects such as cutaneous and urologic problems were common. The studies were generally of a poor quality and reported a large variety of outcomes, which weakens the reliability of the authors' conclusions.
Participants included in the review
Studies of adults with chronic bronchitis or COPD were eligible for inclusion. Studies on the prevention of acute respiratory tract infections in otherwise healthy adults were excluded from the review.
Outcomes assessed in the review
Studies reporting on the efficacy or harm of oral bacterial extracts were eligible for inclusion. Studies reporting only on immunological parameters were excluded. The primary outcome was defined as the prevention of exacerbation. Definitions of exacerbation were taken as reported in the original trials. The secondary outcomes included duration of the exacerbation, improvement of symptoms, rate of hospitalisation due to exacerbation and any adverse effects. The included studies followed up patients for 3 to 12 months.
How were decisions on the relevance of primary studies made?
One reviewer screened all retrieved reports to assess eligibility for inclusion in the review.
Assessment of study quality
The studies were assessed, using a 6-point scale, for adequacy of patient enrolment, sequence generation, concealment of allocation, blinding, how drop-outs were handled and whether an intention-to-treat analysis had been performed. The reviewers considered a quality score of 4 or more to be adequate. Four reviewers independently assessed the methodological quality of the included studies. Any disagreements were resolved by discussion. One reviewer extracted the data from the included studies using standard collection sheets; the other reviewers checked this information. Dichotomous data, i.e. relative risks (RRs) or odds ratios (ORs), on the efficacy or harm of oral bacterial extracts were extracted into 2x2 tables.
Data extraction

Methods of synthesis
How were the studies combined? Pooled RRs or ORs, with their associated 95% confidence intervals (CIs), were calculated through combining studies in a meta-analysis using either a fixed-effect or random-effects model.
How were differences between studies investigated?
Statistical heterogeneity was assessed visually by examining forest plots and formally by calculating the chi-squared test statistic. Potential causes of any identified heterogeneity and the effect of individual studies on the summary effect estimate were explored.
Results of the review
Thirteen RCTs were included in the review (n=2,121 randomised, 1,971 analysed).
The methodological quality of the included studies was generally poor, with a median quality score of 2.
Using a random-effects model, there was no statistically significant difference between the use of active extracts and placebo for the prevention of exacerbation (3 studies); the RR was 0.66 (95% CI: 0.41, 1.08). The presence of statistical heterogeneity was identified (P<0.001).
There was a statistically significant benefit for the average duration of an exacerbation in favour of treatment with active extracts compared with placebo (3 trials); the weighted mean difference was -3.3 days. Significant statistical heterogeneity was detected between the trials.
There was a statistically significant difference in favour of the bacterial extracts, compared with placebo, in improvement assessed by observers (5 studies; RR 0.57, 95% CI: 0.49, 0.66) and patients (2 studies; RR 0.44, 95% CI: 0.31, 0.61).
Skin itching or cutaneous eruptions and urologic problems were experienced significantly more by those receiving bacterial extracts than those receiving placebo. No other significant adverse effects were found, and no significant difference in hospitalisation was identified.
Authors' conclusions
Oral bacterial extracts improved symptoms in patients with chronic bronchitis and COPD. There was insufficient evidence to suggest that they prevented exacerbations. Adverse effects such as cutaneous and urologic problems were common.
CRD commentary
The review question was clear in terms of the study design, intervention, participants and outcomes. A thorough search strategy, without language restrictions, was employed. Some attempt was made to locate unpublished studies; however, the reviewers did not assess the possibility of publication bias. Only one reviewer selected studies for inclusion in the review, thus creating the possibility for error and bias. Methods were used to minimise bias in the assessment of validity and data extraction.
Adequate information on the included studies was presented. Studies reporting adequate data were combined in a metaanalysis, and forest plots were presented for the primary and some secondary outcomes. Statistical heterogeneity was assessed and briefly discussed where it was identified. The sparse nature of the data prevented any formal sensitivity analyses. The authors' conclusions appear to follow from the evidence presented. The studies were generally of a poor quality and reported on a large variety of outcomes, which weakens the reliability of the authors' conclusions.
